KCNQ1 and Hyperglycemia: In conclusion, these results suggest that the new aldose reductase inhibitor benzofuroxane derivative BF-5m may supply cardioprotection from the high glucose induced instability of QT interval components by reducing the cytotoxic effects induced by hyperglycemia on cell viability, by down-regulating miR-1 expression and consequently restoring plasma membrane KCNE1 and KCNQ1 levels in rat heart ventricle H9c2 cells exposed to high glucose.